Abstract:Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide. However, effective diagnostic, therapeutic and prognostic biomarkers are still lacking. Our research group previously revealed through high-throughput sequencing that the serum exosomes miR-133a-3p, miR-206, and miR-549a-3p differ significantly in severe TBI (sTBI), mild or moderate TBI (mTBI), and control groups. However, convincing experimental evidence is lacking. To solve this problem, we used qPCR in this study to further verify the expression levels of serum exosomes miR-133a-3p, miR-206 and miR-549a-3p in TBI patients. The results showed that the serum exosomes miR-206 and miR-549a-3p showed good predictive value as biomarkers of TBI. In addition, in order to further verify whether serum exosomes miR-206 and miR-549a-3p can be used as potential biomarkers in patients with TBI and to understand the mechanism of their possible effects, we further determined the contents of SOD, BDNF, VEGF, VEGI, NSE and S100β in the serum of TBI patients. The results showed that, serum exosomes miR-206 and miR-549a-3p showed good correlation with BDNF, NSE and S100β. In conclusion, serum exosomes miR-206 and miR-549a-3p have the potential to serve as potential biomarkers in patients with TBI.
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to find effective diagnostic, treatment, and prognostic biomarkers for traumatic brain injury (TBI). Specifically, the study aims to verify whether miR - 206 and miR - 549a - 3p in serum exosomes can be potential biomarkers for TBI, and to explore the correlations between these miRNAs and the contents of SOD, BDNF, VEGF, VEGI, NSE, and S100β in the serum of TBI patients.
### Research Background
Traumatic brain injury (TBI) is a global public health problem, especially in low - and middle - income countries, with extremely high mortality and disability rates. Although clinical diagnosis and treatment methods have improved in recent years, such as the Glasgow Coma Scale (GCS), computed tomography (CT), magnetic resonance imaging (MRI), and intracranial pressure monitoring, these methods cannot analyze the patient's condition in real - time and dynamically in the clinical environment. Therefore, the disability and mortality rates of TBI have not been significantly reduced. Therefore, there is an urgent need to identify reliable biomarkers to assess the severity of TBI, predict recovery, and measure the treatment effect.
### Research Objectives
1. **Verify the expression differences of serum exosomal miRNAs**: Further verify the expression differences of serum exosomal miR - 133a - 3p, miR - 206, and miR - 549a - 3p among severe TBI (sTBI), mild or moderate TBI (mTBI), and the control group by qPCR technology.
2. **Explore potential mechanisms**: Further explore the possible action mechanisms of serum exosomal miR - 206 and miR - 549a - 3p by measuring the contents of SOD, BDNF, VEGF, VEGI, NSE, and S100β in the serum of TBI patients.
### Main Findings
1. **Expression differences of miR - 206 and miR - 549a - 3p**:
- The expression level of serum exosomal miR - 206 in the sTBI and mTBI groups was significantly higher than that in the control group (P < 0.01), but there was no significant difference between the sTBI and mTBI groups (P > 0.05).
- The expression level of serum exosomal miR - 549a - 3p in the sTBI group was significantly higher than that in the control group (P < 0.01), while there was no significant difference between the mTBI group and the control group (P > 0.05).
2. **Correlation analysis**:
- Serum exosomal miR - 206 was negatively correlated with S100β and NSE (P < 0.05), positively correlated with BDNF (P < 0.01), and had no significant correlation with SOD and VEGI (P > 0.05).
- Serum exosomal miR - 549a - 3p was negatively correlated with S100β and NSE (P < 0.01), positively correlated with BDNF (P < 0.01), and had no significant correlation with SOD and VEGI (P > 0.05).
3. **Predictive value**:
- The AUC value of serum exosomal miR - 206 in diagnosing sTBI was 0.86 (95% CI 0.79 - 0.94; P < 0.01), the optimal cut - off value was 2.65, the sensitivity was 67%, and the specificity was 93%.
- The AUC value of serum exosomal miR - 549a - 3p in diagnosing sTBI was 0.69 (95% CI 0.58 - 0.81; P < 0.01), the optimal cut - off value was 2.81, the sensitivity was 73%, and the specificity was 76%.
### Conclusion
Serum exosomal miR - 206 and miR - 549a - 3p have the potential to be potential biomarkers for TBI, especially showing good predictive value in diagnosing severe TBI. These findings provide preliminary evidence for further research on the diagnosis and treatment of TBI.